Cold Indication For Antihistamine Monograph Expected This Year – DNDP Director Michele
This article was originally published in The Tan Sheet
Executive Summary
FDA this year will publish an antihistamine monograph rule stemming from a partnership with Canada, says Theresa Michele, director of the Division of Nonprescription Drug Products. At a recent CHPA conference, Michele suggested FDA will parlay strong momentum and internal improvements from 2015 into 2016 progress.
You may also be interested in...
FDA Plans To Publish 'Novel' OTC Switch NPRM In May 2020
Agency list in HHS Unified Agenda also states intent to publish before end of 2019 an NPRM to add the common cold indication to certain OTC monograph antihistamine ingredients. Nonbinding timelines also included for NPRM on clarifying regarding when studies to evaluate drug uses of products marketed as foods, supplements or cosmetics are subject to IND reviews.
FDA Busy Sorting OTC Monograph Ingredients Anticipating System Overhaul
FDA has yet to finalize about one-third of its OTC monographs and several hundred ingredients do not have a final GRASE determination. Sorting will help the agency determine which of the 800 active OTC monograph ingredients are designated as needing more information to establish GRASE under a faster system based on administrative orders.
FDA Busy Sorting OTC Monograph Ingredients Anticipating System Overhaul
FDA has yet to finalize about one-third of its OTC monographs and several hundred ingredients do not have a final GRASE determination. Sorting will help the agency determine which of the 800 active OTC monograph ingredients are designated as needing more information to establish GRASE under a faster system based on administrative orders.